Twist Bioscience三季度收入超指引但每股亏损大于预期

Oil falls over 4% as Trump calls off Iran strike, announces fresh talks
Introduction & Market Context
Twist Bioscience (NASDAQ:TWST) presented its fiscal third-quarter 2026 financial results on August 3, 2026, reporting revenue of $118.4 million that exceeded guidance while advancing toward a key profitability milestone. The synthetic biology company delivered its 14th consecutive quarter of sequential revenue growth, though shares fell 7.7% in premarket trading to $84.50 as investors focused on a wider-than-expected adjusted loss of $0.56 per share versus the $0.48 consensus estimate.
The mixed results highlight a tension between Twist’s strong top-line momentum and the market’s demand for clearer evidence of sustained profitability. While the company beat its own revenue guidance of $114-115 million and maintained 23% year-over-year growth, the earnings miss underscored ongoing cost pressures as the company invests in capacity expansion and new product development.
Quarterly Performance Highlights
Twist’s fiscal third-quarter 2026 performance demonstrated continued revenue momentum across its business segments. As shown in the following chart tracking the company’s consistent sequential revenue growth over 14 quarters, total revenue reached $118.4 million, comprising $61.8 million from NGS Applications and $56.6 million from DNA Synthesis & Protein Solutions.
The company reported an adjusted gross margin of 52.8%, representing a 120-basis-point sequential improvement from the prior quarter. Adjusted EBITDA came in at a loss of $11.3 million, demonstrating meaningful progress toward the company’s target of reaching breakeven in the fiscal fourth quarter of 2026. Cash, cash equivalents, and short-term investments totaled $167 million as of June 30, 2026.
The following breakdown of Q3 FY26 financial highlights illustrates the company’s key performance metrics for the quarter.
Segment Performance Analysis
Twist’s DNA Synthesis & Protein Solutions segment delivered particularly strong performance, generating $56.6 million in revenue with 39% year-over-year growth and 6% sequential growth. The company physically shipped approximately 369,000 genes during the quarter and reported sequential growth for genes manufactured for data characterization, supporting its AI-enabled drug discovery initiatives.
The NGS Applications segment produced $61.8 million in revenue, up 12% year-over-year and 8% sequentially. A notable highlight was the Twist Comprehensive Viral Research Panel’s role in identifying a rare strain of Ebola virus in the Democratic Republic of Congo that had evaded standard PCR tests, demonstrating the platform’s capabilities in emerging infectious disease detection.
As shown in the following industry revenue breakdown, the therapeutics segment led growth with $40.4 million in revenue, up 49% year-over-year, while diagnostics contributed $43.8 million with 15% growth.
The geographic revenue distribution shows the Americas region continuing to represent the largest portion of total revenue, followed by EMEA and APAC, with consistent growth across all regions over the company’s fiscal history.
Strategic Growth Drivers
Twist positioned AI-enabled drug discovery as a transformative growth engine, projecting triple-digit percentage order growth for fiscal 2026 versus fiscal 2025, with expectations to meet or exceed targets. The company expressed confidence in repeating this performance in fiscal 2027 based on an expanding customer funnel that includes repeat programs, new customer acquisition, and new organizations entering life sciences.
The following illustration demonstrates how AI aims to reduce the substantial costs and improve the high attrition rates that characterize traditional drug discovery, where approximately 5,000-10,000 compounds are screened to yield one approved medicine at a capitalized cost of roughly $1.8 billion.
Twist’s AI-enabled discovery process creates a durable revenue model through an iterative cycle of design, build, test, and learn. As shown in the following diagram, customers generate millions of candidate DNA sequences using AI, which Twist synthesizes and characterizes through high-throughput processes. The assay data then informs the next design round, driving repeat orders and creating recurring value.
The company highlighted competitive advantages including complex DNA synthesis at scale, protein expression capabilities, high-quality characterization data, and consistent results delivered at the speed modern discovery requires. Management noted that customers are now engaging more deeply, moving beyond simple supplier relationships to collaborative scientific partnerships.
Operational Excellence and Manufacturing Discipline
Twist demonstrated significant operational improvements over the past three years, positioning the company to expand capacity while reducing costs. The following chart illustrates quantitative improvements across three critical metrics: cost per million oligos, chemical waste, and turnaround time.
The company achieved approximately 60% cost reduction, 70% waste reduction, and 73% turnaround time reduction while increasing oligonucleotide writer capacity by roughly fourfold. These improvements were measured for approximately 1 million oligos at femtomole scale and reflect the company’s focus on building manufacturing discipline rather than optimizing for single-quarter results.
During an early access period from April 15 to July 21, 2026, Twist’s complex gene synthesis offering processed over 1,800 complex genes across more than 100 orders, with the majority delivered in 12 days. The company emphasized simple automated ordering, complete transparency, predictable turnaround times, and reliable synthesis at affordable pricing.
Market Opportunity and Long-Term Potential
Twist outlined substantial addressable market opportunities extending to 2030, with serviceable addressable markets totaling approximately $13 billion across its two main business lines. As shown in the following market opportunity breakdown, NGS Applications represents a $6 billion SAM with a total addressable market exceeding $90 billion, driven by oncology diagnostics, microarray, academic research, and rare disease applications with a blended market growth rate of approximately 14%.
The DNA Synthesis and Protein Solutions segment, including AI-enabled drug discovery, nucleic acid therapeutics, and traditional synthesis services, represents a $7 billion-plus SAM and $18 billion TAM with an 11% blended growth rate. The company identified oncology diagnostics as the largest single opportunity at $3.6 billion, followed by antibody discovery services at $2.5 billion.
Financial Trajectory and Path to Profitability
The company’s financial progression demonstrates steady improvement in key metrics over multiple years. The following comprehensive view of annual and quarterly performance shows revenue growth from $90.1 million in fiscal 2020 to guidance of $456-457 million for fiscal 2026, while gross margins expanded from 32% to over 52%.
Twist’s progress toward adjusted EBITDA breakeven is illustrated in the following quarterly trend chart, showing improvement from a loss of $26.4 million in Q4 fiscal 2023 to $11.3 million in Q3 fiscal 2026, supported by expanding gross margins and disciplined operating expense management.
The company reported that adjusted R&D and SG&A expenses totaled $79.9 million in Q3 FY26, with management indicating that some costs were one-time in nature related to employee transitions. Chief Financial Officer Adam Laponis stated that the company expects operating expenses to improve in the fourth quarter while continuing to support growth investments.
Guidance and Forward Outlook
Twist raised its full-year fiscal 2026 revenue guidance to $456-457 million, representing 21% year-over-year growth, up $12 million at the midpoint from prior guidance. The company expects gross margins to exceed 52% for the full year. As shown in the following guidance slide, fourth-quarter revenue is projected at $123-124 million, representing approximately 25% year-over-year growth at the midpoint.
Most significantly, Twist expects to achieve adjusted EBITDA breakeven in the fiscal fourth quarter of 2026, marking a key inflection point in the company’s financial trajectory. Management projected sequential revenue growth in both DSPS and NGS Applications segments, with DSPS growth driven by therapeutics and AI-enabled drug discovery.
Looking to fiscal 2027, the company expressed confidence in achieving triple-digit percentage order growth for AI-enabled drug discovery based on a robust customer funnel. The company plans to provide full-year fiscal 2027 guidance in November 2026.
Strategic Priorities and Execution Framework
The presentation concluded with eight key strategic imperatives summarizing Twist’s execution focus. As illustrated in the following summary slide, the company emphasized its 23% year-over-year revenue growth for the 14th consecutive quarter, projections to more than double revenue from organic sources by 2031, and the path to over 60% gross margins as the business matures.
CEO Emily Leproust noted that the company is seeing a broader and more mature AI-driven customer base, with customers now engaging in more formal agreements and transparent discussions about their needs. She emphasized that Twist has evolved beyond being simply a supplier to providing comprehensive solutions, with customers engaging directly with the company’s chief scientific officer on drug discovery work.
President and COO Patrick Finn highlighted the company’s manufacturing discipline, stating: "We do not optimize for a single quarter. We focus on building a stronger company every quarter." This approach reflects Twist’s strategy of balancing near-term profitability goals with investments in capacity, digital capabilities, and product development to support long-term growth.
Investor Considerations
While Twist’s presentation emphasized strong revenue momentum and progress toward profitability, the market’s negative premarket reaction suggests investors remain focused on the pace of margin expansion and the sustainability of the path to breakeven. The company’s adjusted loss of $0.56 per share, compared to expectations of $0.48, indicates that operating expenses remain elevated as Twist invests in scaling its platform.
Key risks include execution challenges in the emerging AI-enabled drug discovery business, competitive pressure from rivals such as GenScript, potential customer concentration in certain segments, and the need to demonstrate that recent operational improvements can translate into sustained profitability. The company’s high beta of 2.11 reflects significant volatility, and despite the premarket decline, shares remain up 189% year-to-date.
Twist’s ability to achieve adjusted EBITDA breakeven in the fourth quarter will be closely watched as a critical test of whether the company can convert its strong revenue growth into improving profitability while maintaining investments in future growth opportunities. The convergence of expanding gross margins, disciplined operating expense management, and accelerating demand for AI-enabled drug discovery tools positions the company at a potential inflection point, though investors will require evidence of sustained execution to fully embrace the growth narrative.
Full presentation:
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.